Breast Cancer
Breast cancer could benefit from use of taxanes as adjuvant chemotherapy
Published in Women's Health Weekly, July 27th, 2006
"The magnitude of the survival benefit of taxanes as adjuvant chemotherapy for early breast cancer is still unclear. A pooled analysis of Phase III trials was performed to assess the advantages that adjuvant taxane chemotherapy has over standard chemotherapy," investigators in Italy reported.
"All Phase III trials were considered eligible," explained E. Bria and colleagues, Regina Elena Institute for Cancer Research. "A pooled analysis was accomplished and event-based relative risk ratios (RR) with 95% confidence intervals (95%...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Allergy & Immunology
Avoiding antigens during lactation may not prevent occurrence of allergies in children - Breast Cancer
Racial differences in breast cancer risk may indicate need for updated risk estimates - Breast Cancer
Tamoxifen-treated breast cancer may influence progression of atypical endometrial lesions - Renal Cell Carcinoma
Risk of kidney cancer is associated with obesity in women - Uterine Cancer
One third of women treated with tamoxifen develop uterine cancer more than 12 months after therapy - Anesthesia
Laryngeal secretions may not be overly affected by topical anesthesia - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
